Paul C Lambert

List of Publications by Citations

149 papers	9,361 citations	44 h-index	95 g-index
158 ext. papers	10,969 ext. citations	4.8 avg, IF	6.29 L-index

#	Paper	IF	Citations
149	What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Statistics in Medicine*, **2004**, 23, 1351-75	2.3	1124
148	Meta-analysis of individual participant data: rationale, conduct, and reporting. *BMJ, The*, **2010**, 340, c221	5.9	925
147	Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. *BMJ, The*, **2007**, 334, 299	5.9	773
146	Further Development of Flexible Parametric Models for Survival Analysis. *The Stata Journal*, **2009**, 9, 265-290	3.5	410
145	Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. *Journal of Clinical Oncology*, **2016**, 34, 2851-7	2.2	390
144	How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. *Statistics in Medicine*, **2005**, 24, 2401-28	2.3	352
143	Changes in the risk of death after HIV seroconversion compared with mortality in the general population. *JAMA - Journal of the American Medical Association*, **2008**, 300, 51-9	27.4	339
142	Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. *Lancet Oncology, The*, **2019**, 20, 1493-1505	21.7	270
141	Oral prednisolone for preschool children with acute virus-induced wheezing. *New England Journal of Medicine*, **2009**, 360, 329-38	59.2	241
140	Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. *BMJ, The*, **2008**, 336, 1180-5	5.9	197
139	Meta-analysis of continuous outcomes combining individual patient data and aggregate data. *Statistics in Medicine*, **2008**, 27, 1870-93	2.3	185
138	Flexible parametric models for relative survival, with application in coronary heart disease. *Statistics in Medicine*, **2007**, 26, 5486-98	2.3	161
137	Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. *Lancet, The*, **2003**, 362, 1433-8	40	156
136	Estimating and modeling the cure fraction in population-based cancer survival analysis. *Biostatistics* , **2007**, 8, 576-94	3.7	155
135	Bivariate random-effects meta-analysis and the estimation of between-study correlation. *BMC Medical Research Methodology*, **2007**, 7, 3	4.7	154
134	A systematic review of molecular and biological tumor markers in neuroblastoma. *Clinical Cancer Research*, **2004**, 10, 4-12	12.9	148
133	Meta-analysis of heterogeneously reported trials assessing change from baseline. *Statistics in Medicine*, **2005**, 24, 3823-44	2.3	145

132	Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. *British Journal of Haematology*, **2013**, 162, 509-16	4.5	127
131	Screening and cervical cancer cure: population based cohort study. *BMJ, The*, **2012**, 344, e900	5.9	126
130	Evidence-based sample size calculations based upon updated meta-analysis. *Statistics in Medicine*, **2007**, 26, 2479-500	2.3	104
129	Meta-analysis of rare and adverse event data. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2002**, 2, 367-79	2.2	93
128	Choosing the relative survival method for cancer survival estimation. *European Journal of Cancer*, **2011**, 47, 2202-10	7.5	92
127	Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. *Journal of Clinical Oncology*, **2015**, 33, 2288-95	2.2	84
126	Estimating the loss in expectation of life due to cancer using flexible parametric survival models. *Statistics in Medicine*, **2013**, 32, 5286-300	2.3	79
125	Estimating the crude probability of death due to cancer and other causes using relative survival models. *Statistics in Medicine*, **2010**, 29, 885-95	2.3	78
124	Flexible parametric modelling of cause-specific hazards to estimate cumulative incidence functions. *BMC Medical Research Methodology*, **2013**, 13, 13	4.7	73
123	Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. *BMC Medical Research Methodology*, **2011**, 11, 96	4.7	73
122	Modeling of the Cure Fraction in Survival Studies. *The Stata Journal*, **2007**, 7, 351-375	3.5	72
121	Automated, ambulatory, or conventional blood pressure measurement in pregnancy: which is the better predictor of severe hypertension?. *American Journal of Obstetrics and Gynecology*, **1998**, 178, 521-6	6.4	71
120	Joint Modeling of Longitudinal and Survival Data. *The Stata Journal*, **2013**, 13, 165-184	3.5	70
119	Simulating biologically plausible complex survival data. *Statistics in Medicine*, **2013**, 32, 4118-34	2.3	63
118	Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study. *BMC Medical Research Methodology*, **2011**, 11, 4	4.7	63
117	A population-based comparison of the survival of patients with colorectal cancer in England, Norway and Sweden between 1996 and 2004. *Gut*, **2011**, 60, 1087-93	19.2	63
116	Breast cancer, sickness absence, income and marital status. A study on life situation 1 year prior diagnosis compared to 3 and 5 years after diagnosis. *PLoS ONE*, **2011**, 6, e18040	3.7	57
115	The use of restricted cubic splines to approximate complex hazard functions in the analysis of time-to-event data: a simulation study. *Journal of Statistical Computation and Simulation*, **2015**, 85, 777-793	0.9	55

114	Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations. *Medical Decision Making*, **2014**, 34, 387-402	2.5	55
113	Comparison of methods for calculating relative survival in population-based studies. *Cancer Epidemiology*, **2012**, 36, 16-21	2.8	51
112	Additive and multiplicative covariate regression models for relative survival incorporating fractional polynomials for time-dependent effects. *Statistics in Medicine*, **2005**, 24, 3871-85	2.3	49
111	Parametric multistate survival models: Flexible modelling allowing transition-specific distributions with application to estimating clinically useful measures of effect differences. *Statistics in Medicine*, **2017**, 36, 4719-4742	2.3	47
110	Individual patient data meta-analysis of survival data using Poisson regression models. *BMC Medical Research Methodology*, **2012**, 12, 34	4.7	46
109	Bayesian implementation of a genetic model-free approach to the meta-analysis of genetic association studies. *Statistics in Medicine*, **2005**, 24, 3845-61	2.3	46
108	Comparison of different approaches to estimating age standardized net survival. *BMC Medical Research Methodology*, **2015**, 15, 64	4.7	45
107	A general framework for parametric survival analysis. *Statistics in Medicine*, **2014**, 33, 5280-97	2.3	45
106	Relative survival: what can cardiovascular disease learn from cancer?. *European Heart Journal*, **2008**, 29, 941-7	9.5	45
105	Flexible parametric joint modelling of longitudinal and survival data. *Statistics in Medicine*, **2012**, 31, 4456-71	2.3	40
104	Temporal trends in the proportion cured for cancer of the colon and rectum: a population-based study using data from the Finnish Cancer Registry. *International Journal of Cancer*, **2007**, 121, 2052-9	7.5	40
103	A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. *Journal of Clinical Epidemiology*, **2005**, 58, 26-40	5.7	37
102	Colorectal cancer survival in socioeconomic groups in England: variation is mainly in the short term after diagnosis. *European Journal of Cancer*, **2012**, 48, 46-53	7.5	35
101	How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. *Cancer Causes and Control*, **2013**, 24, 505-15	2.8	35
100	Predicting costs over time using Bayesian Markov chain Monte Carlo methods: an application to early inflammatory polyarthritis. *Health Economics (United Kingdom)*, **2007**, 16, 37-56	2.4	35
99	Urine protein estimation in hypertensive pregnancy: which thresholds and laboratory assay best predict clinical outcome?. *Hypertension in Pregnancy*, **2005**, 24, 291-302	2	35
98	The role of observer error in antenatal dipstick proteinuria analysis. *BJOG: an International Journal of Obstetrics and Gynaecology*, **1999**, 106, 1177-80	3.7	35
97	Quantifying differences in breast cancer survival between England and Norway. *Cancer Epidemiology*, **2011**, 35, 526-33	2.8	33

96	Birth weight and 24-hour ambulatory blood pressure in nonproteinuric hypertensive pregnancy. *American Journal of Obstetrics and Gynecology*, **2000**, 183, 633-7	6.4	33
95	A Bayesian approach to Markov modelling in cost-effectiveness analyses: application to taxane use in advanced breast cancer. *Journal of the Royal Statistical Society Series A: Statistics in Society*, **2003**, 166, 389-405	2.1	32
94	Transmission of Neurodegenerative Disorders Through Blood Transfusion: A Cohort Study. *Annals of Internal Medicine*, **2016**, 165, 316-24	8	32
93	Estimating the impact of a cancer diagnosis on life expectancy by socio-economic group for a range of cancer types in England. *British Journal of Cancer*, **2017**, 117, 1419-1426	8.7	30
92	Sensitivity analyses allowed more appropriate and reliable meta-analysis conclusions for multiple outcomes when missing data was present. *Journal of Clinical Epidemiology*, **2004**, 57, 911-24	5.7	27
91	Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling. *Medical Decision Making*, **2007**, 27, 471-90	2.5	26
90	Randomised controlled trial of the effectiveness of feedback in improving test ordering in general practice. *Scandinavian Journal of Primary Health Care*, **2003**, 21, 219-23	2.7	24
89	Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study. *Statistical Methods in Medical Research*, **2018**, 27, 765-784	2.3	23
88	Proportion cured models applied to 23 cancer sites in Norway. *International Journal of Cancer*, **2013** , 132, 1700-10	7.5	23
87	The impact of under and over-recording of cancer on death certificates in a competing risks analysis: a simulation study. *Cancer Epidemiology*, **2013**, 37, 11-9	2.8	23
86	Analysis of ambulatory blood pressure monitor data using a hierarchical model incorporating restricted cubic splines and heterogeneous within-subject variances. *Statistics in Medicine*, **2001**, 20, 3789-805	2.3	23
85	Effect of concentration and biochemical assay on the accuracy of urine dipsticks in hypertensive pregnancies. *Hypertension in Pregnancy*, **2001**, 20, 205-17	2	23
84	stgenreg: AStataPackage for General Parametric Survival Analysis. *Journal of Statistical Software*, **2013**, 53,	7.3	23
83	The loss in expectation of life after colon cancer: a population-based study. *BMC Cancer*, **2015**, 15, 412	4.8	20
82	Adjusting for the proportion of cancer deaths in the general population when using relative survival: a sensitivity analysis. *Cancer Epidemiology*, **2012**, 36, 148-52	2.8	20
81	Simulating Complex Survival Data. *The Stata Journal*, **2012**, 12, 674-687	3.5	20
80	Estimating net survival in population-based cancer studies. *International Journal of Cancer*, **2013**, 133, 519-21	7.5	20
79	Automated blood pressure measurement as a predictor of proteinuric pre-eclampsia. *BJOG: an International Journal of Obstetrics and Gynaecology*, **1997**, 104, 559-62	3.7	20

78	Temporal trends in mortality from diseases of the circulatory system after treatment for Hodgkin lymphoma: a population-based cohort study in Sweden (1973 to 2006). *Journal of Clinical Oncology*, **2013**, 31, 1435-41	2.2	19
77	Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: a population-based study. *Cancer Epidemiology*, **2014**, 38, 93-9	2.8	18
76	Partitioning of excess mortality in population-based cancer patient survival studies using flexible parametric survival models. *BMC Medical Research Methodology*, **2012**, 12, 86	4.7	18
75	Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based study. *British Journal of Haematology*, **2010**, 148, 918-24	4.5	18
74	A Bayesian approach to a general regression model for ROC curves. *Medical Decision Making*, **1998**, 18, 436-43	2.5	18
73	Joint modelling of longitudinal and survival data: incorporating delayed entry and an assessment of model misspecification. *Statistics in Medicine*, **2016**, 35, 1193-209	2.3	18
72	Flexible parametric modelling of the cause-specific cumulative incidence function. *Statistics in Medicine*, **2017**, 36, 1429-1446	2.3	17
71	Understanding the impact of socioeconomic differences in colorectal cancer survival: potential gain in life-years. *British Journal of Cancer*, **2019**, 120, 1052-1058	8.7	17
70	Prognostic value of admission blood glucose concentration and diabetes diagnosis on survival after acute myocardial infarction: results from 4702 index cases in routine practice. *Clinical Science*, **2010**, 118, 527-35	6.5	16
69	Robustness of individual and marginal model-based estimates: A sensitivity analysis of flexible parametric models. *Cancer Epidemiology*, **2019**, 58, 17-24	2.8	15
68	A Flexible Parametric Competing-risks Model Using a Direct Likelihood Approach for the Cause-specific Cumulative Incidence Function. *The Stata Journal*, **2017**, 17, 462-489	3.5	14
67	Adjusting for measurement error in baseline prognostic biomarkers included in a time-to-event analysis: a joint modelling approach. *BMC Medical Research Methodology*, **2013**, 13, 146	4.7	14
66	Estimating the cost-effectiveness of an intervention in a clinical trial when partial cost information is available: a Bayesian approach. *Health Economics (United Kingdom)*, **2008**, 17, 67-81	2.4	14
65	Trends in cancer survival in the Nordic countries 1990-2016: the NORDCAN survival studies. *Acta Oncologica*, **2020**, 59, 1266-1274	3.2	14
64	Projecting cancer incidence using age-period-cohort models incorporating restricted cubic splines. *International Journal of Biostatistics*, **2012**, 8, 33	1.3	13
63	Validation of the DCA 2000 microalbumin:creatinine ratio urinanalyzer for its use in pregnancy and preeclampsia. *Hypertension in Pregnancy*, **2003**, 22, 77-92	2	13
62	Urinary microalbumin/creatinine ratios: reference range in uncomplicated pregnancy. *Clinical Science*, **2003**, 104, 103-7	6.5	13
61	Incidence of non-specific abdominal pain in children during school term: population survey based on discharge diagnoses **1999**, 318, 1455-1455		13

60	Direct likelihood inference on the cause-specific cumulative incidence function: A flexible parametric regression modelling approach. *Statistics in Medicine*, **2018**, 37, 82-97	2.3	12
59	Analysis, power and design of antimicrobial resistance surveillance studies, taking account of inter-centre variation and turnover. *Journal of Antimicrobial Chemotherapy*, **2008**, 62 Suppl 2, ii29-39	5.1	12
58	Loss in life expectancy and gain in life years as measures of cancer impact. *Cancer Epidemiology*, **2019**, 60, 168-173	2.8	11
57	Modelling time to death or discharge in neonatal care: an application of competing risks. *Paediatric and Perinatal Epidemiology*, **2013**, 27, 426-33	2.7	11
56	Providing more up-to-date estimates of patient survival: a comparison of standard survival analysis with period analysis using life-table methods and proportional hazards models. *Journal of Clinical Epidemiology*, **2004**, 57, 14-20	5.7	11
55	Association of fractures with the incidence of amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2017**, 18, 419-425	3.6	10
54	Adjusting Expected Mortality Rates Using Information From a Control Population: An Example Using Socioeconomic Status. *American Journal of Epidemiology*, **2018**, 187, 828-836	3.8	10
53	Capturing simple and complex time-dependent effects using flexible parametric survival models: A simulation study. *Communications in Statistics Part B: Simulation and Computation*, **2019**, 1-17	0.6	10
52	The application of cure models in the presence of competing risks: a tool for improved risk communication in population-based cancer patient survival. *Epidemiology*, **2014**, 25, 742-8	3.1	10
51	Bed occupancy rates and hospital-acquired Clostridium difficile infection: a cohort study. *Infection Control and Hospital Epidemiology*, **2013**, 34, 1062-9	2	10
50	The analysis of peak expiratory flow data using a three-level hierarchical model. *Statistics in Medicine*, **2004**, 23, 3821-39	2.3	10
49	Strcs: A Command for Fitting Flexible Parametric Survival Models on the Log-hazard Scale. *The Stata Journal*, **2016**, 16, 989-1012	3.5	10
48	Flexible Parametric Illness-Death Models. *The Stata Journal*, **2013**, 13, 759-775	3.5	9
47	Fitting and Modeling Cure in Population-Based Cancer Studies within the Framework of Flexible Parametric Survival Models. *The Stata Journal*, **2012**, 12, 623-638	3.5	9
46	Comment on article by Browne and Draper. *Bayesian Analysis*, **2006**, 1, 543	2.3	9
45	stpm2cr: A flexible parametric competing risks model using a direct likelihood approach for the cause-specific cumulative incidence function. *The Stata Journal*, **2017**, 17, 462-489	3.5	9
44	The estimation and modelling of cause-specific cumulative incidence functions using time-dependent weights. *The Stata Journal*, **2017**, 17, 181-207	3.5	9
43	A flexible parametric approach to examining spatial variation in relative survival. *Statistics in Medicine*, **2016**, 35, 5448-5463	2.3	9

42	Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators. *Journal of Clinical Oncology*, **2018**, 36, 2718-2725	2.2	9
41	Potential gain in life years for Swedish women with breast cancer if stage and survival differences between education groups could be eliminated - Three what-if scenarios. *Breast*, **2019**, 45, 75-81	3.6	8
40	Temporal recalibration for improving prognostic model development and risk predictions in settings where survival is improving over time. *International Journal of Epidemiology*, **2020**, 49, 1316-1325	7.8	8
39	Familial coaggregation of Alzheimer's disease and Parkinson's disease: systematic review and meta-analysis. *Neuroepidemiology*, **2014**, 42, 69-80	5.4	8
38	Urinary microalbumin/creatinine ratios: reference range in uncomplicated pregnancy. *Clinical Science*, **2003**, 104, 103-107	6.5	7
37	Marginal measures and causal effects using the relative survival framework. *International Journal of Epidemiology*, **2020**, 49, 619-628	7.8	6
36	Loss in working years after a breast cancer diagnosis. *British Journal of Cancer*, **2018**, 118, 738-743	8.7	6
35	Illustration of different modelling assumptions for estimation of loss in expectation of life due to cancer. *BMC Medical Research Methodology*, **2019**, 19, 145	4.7	6
34	Exploring the impact of cancer registry completeness on international cancer survival differences: a simulation study. *British Journal of Cancer*, **2021**, 124, 1026-1032	8.7	6
33	Impact on survival of modelling increased surgical resection rates in patients with non-small-cell lung cancer and cardiovascular comorbidities: a VICORI study. *British Journal of Cancer*, **2020**, 123, 471-479	8.7	5
32	Estimation of age-standardized net survival, even when age-specific data are sparse. *Cancer Epidemiology*, **2020**, 67, 101745	2.8	5
31	InterPreT cancer survival: A dynamic web interactive prediction cancer survival tool for health-care professionals and cancer epidemiologists. *Cancer Epidemiology*, **2018**, 56, 46-52	2.8	5
30	Placental weight and breast cancer survival in young women. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 777-83	4	5
29	Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study. *British Journal of Cancer*, **2021**, 124, 671-677	8.7	5
28	Where Next for Evidence Synthesis of Prognostic Marker Studies? Improving the Quality and Reporting of Primary Studies to Facilitate Clinically Relevant Evidence-Based Results **2007**, 39-58		4
27	Conditional crude probabilities of death for English cancer patients. *British Journal of Cancer*, **2019**, 121, 883-889	8.7	3
26	The impact of excluding or including Death Certificate Initiated (DCI) cases on estimated cancer survival: A simulation study. *Cancer Epidemiology*, **2021**, 71, 101881	2.8	3
25	Temporal trends in treatment-related incidence of diseases of the circulatory system among Hodgkin lymphoma patients. *International Journal of Cancer*, **2019**, 145, 1200-1208	7.5	2

24	Can different definitions of date of cancer incidence explain observed international variation in cancer survival? An ICBP SURVMARK-2 study. *Cancer Epidemiology*, **2020**, 67, 101759	2.8	2
23	Rebuttal to editorial saying cancer survival statistics are misleading. *BMJ, The*, **2011**, 343, d4214	5.9	2
22	Minimum sample size calculations for external validation of a clinical prediction model with a time-to-event outcome.. *Statistics in Medicine*, **2021**,	2.3	2
21	Temporal Trends in Chronic Myeloid Leukemia Outcome Using the Loss in Expectation of Life: A Swedish Population-Based Study. *Blood*, **2015**, 126, 2779-2779	2.2	2
20	Understanding disparities in cancer prognosis: An extension of mediation analysis to the relative survival framework. *Biometrical Journal*, **2021**, 63, 341-353	1.5	2
19	Reference-adjusted and standardized all-cause and crude probabilities as an alternative to net survival in population-based cancer studies. *International Journal of Epidemiology*, **2020**, 49, 1614-1623	7.8	2
18	Individual participant data meta-analysis for external validation, recalibration, and updating of a flexible parametric prognostic model. *Statistics in Medicine*, **2021**, 40, 3066-3084	2.3	2
17	Reply to D. Pulte et al. *Journal of Clinical Oncology*, **2017**, 35, 696-697	2.2	1
16	Comments on Q trying to be precise about vagueness Q by Stephen Senn, Statistics in Medicine 2007; 26:1417-1430. *Statistics in Medicine*, **2008**, 27, 619-22, author reply 622-4	2.3	1
15	Case-ascertainment of acute myocardial infarction hospitalisations in cancer patients: a cohort study using English linked electronic health data. *European Heart Journal Quality of Care & Clinical Outcomes*, **2021**,	4.6	1
14	Data Resource Profile: The Virtual Cardio-Oncology Research Initiative (VICORI) linking national English cancer registration and cardiovascular audits. *International Journal of Epidemiology*, **2021**,	7.8	1
13	A multistate model incorporating estimation of excess hazards and multiple time scales. *Statistics in Medicine*, **2021**, 40, 2139-2154	2.3	1
12	Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models. *BMC Medical Research Methodology*, **2021**, 21, 52	4.7	1
11	Potential bias introduced by not including multiple time-scales in survival analysis: a simulation study. *Communications in Statistics Part B: Simulation and Computation*,1-14	0.6	1
10	Non-parametric estimation of reference adjusted, standardised probabilities of all-cause death and death due to cancer for population group comparisons.. *BMC Medical Research Methodology*, **2022**, 22, 2	4.7	0
9	Development of a dynamic interactive web tool to enhance understanding of multi-state model analyses: MSMplus. *BMC Medical Research Methodology*, **2021**, 21, 262	4.7	0
8	A way to explore the existence of "immortals" in cancer registry data - An illustration using data from ICBP SURVMARK-2.. *Cancer Epidemiology*, **2021**, 76, 102085	2.8	0
7	Relaxing the assumption of constant transition rates in a multi-state model in hospital epidemiology. *BMC Medical Research Methodology*, **2021**, 21, 16	4.7	0

6	Inverse probability weighting and doubly robust standardization in the relative survival framework. *Statistics in Medicine*, **2021**, 40, 6069-6092	2.3	0
5	Reply to Letter to the Editor by Remontet et al. *Statistics in Medicine*, **2015**, 34, 3378-80	2.3	
4	Loss in working years after a breast cancer diagnosis: A population-based study (Sweden).. *Journal of Clinical Oncology*, **2017**, 35, 209-209	2.2	
3	Temporal Trends in the Proportion Cured Among Patients Diagnosed with Acute Myeloid Leukemia in Sweden 1973-2001, a Population-Based Study.. *Blood*, **2009**, 114, 1378-1378	2.2	
2	Direct modelling of age standardized marginal relative survival through incorporation of time-dependent weights. *BMC Medical Research Methodology*, **2021**, 21, 84	4.7	
1	Assessing the impact of including variation in general population mortality on standard errors of relative survival and loss in life expectancy.. *BMC Medical Research Methodology*, **2022**, 22, 130	4.7	